https://oncologyreviews.org/index.php/or/issue/feed Oncology Reviews 2019-01-18T00:34:58+01:00 Paola Granata paola.granata@pagepress.org Open Journal Systems <p><strong>Oncology Reviews</strong> is an Open Access, peer-reviewed, international journal that publishes authoritative state-of-the-art reviews on preclinical and clinical aspects of oncology.</p> <p>The journal provide up-to-date information on the latest achievements in different fields of oncology for both practising clinicians and basic researchers. <strong>Oncology Reviews</strong> aims at being international in scope and readership, as reflected also by its Editorial Board, gathering the world leading experts in both pre-clinical research and everyday clinical practice.</p> <p>The journal is open for publication of supplements, monothematic issues and for publishing abstracts of scientific meetings; conditions can be obtained from the Editor-in-Chief or the publisher.</p> <p>The journal was previously published by Springer Italy; since 2012 <strong>Oncology Reviews</strong> passed on to PAGEPress.&nbsp;</p> <p>This journal does not apply the article processing charge&nbsp;to Authors as it is supported by institutional funds.</p> https://oncologyreviews.org/index.php/or/article/view/376 Breast cancer, human immunodeficiency virus and highly active antiretroviral treatment; implications for a high-rate seropositive region 2019-01-18T00:34:58+01:00 Subash Chirkut chirkut@ukzn.ac.za <p>Sub-Saharan Africa is the region in the world with the most people infected with the human immunodeficiency virus (HIV). The incidence of breast cancer is also rising in the region. This transcript focusses on the burden of these two diseases when they converge in the same populace. This comprehensive literature review of the topic suggests a trend towards an increasing incidence of breast cancer in the HIV-infected population, and the rationale for such a tendency is hypothesized, especially in the context of the availability of highly active antiretroviral therapy. Besides the age at diagnosis, all other clinical characteristics appear to be similar in HIV-positive and HIV-negative breast cancer populations. Outcomes of the different treatment modalities for breast cancer in HIV-positive patients are also appraised and finally innovative areas of future research are suggested along with plausible recommendations.</p> 2019-01-14T12:04:00+01:00 ##submission.copyrightStatement## https://oncologyreviews.org/index.php/or/article/view/387 Survival outcomes of patients with cervical cancer and accompanying hydronephrosis: A systematic review of the literature 2019-01-18T00:34:57+01:00 Vasilios Pergialiotis pergialiotis@yahoo.com Ioannis Bellos pergialiotis@yahoo.com Nikolaos Thomakos pergialiotis@yahoo.com Dimitrios Haidopoulos pergialiotis@yahoo.com Despina N. Perrea pergialiotis@yahoo.com Konstantinos Kontzoglou pergialiotis@yahoo.com Georgios Daskalakis pergialiotis@yahoo.com Alexandros Rodolakis pergialiotis@yahoo.com <p>Hydronephrosis is a sign of advanced stage disease in patients with cervical cancer. Its presence is believed to negatively affect the survival of patients. To date, however, consensus in this field is still lacking. The purpose of the present systematic review is to gather the available data and to provide directions for future research in the field. We systematically searched Medline, Scopus, Clinicaltrials.gov, EMBASE, Cochrane Central Register of Controlled Trials CENTRA and Google Scholar databases from inception till June 2018. Overall, 22 studies were included in the present systematic review that evaluated outcomes from 8521 patients with cervical cancer. The findings of our systematic review support that hydronephrosis negatively affects the overall survival of cervical cancer patients. Specifically, the reported 5-year OS hazards ratio for hydronephrosis ranged between 1.34 and 3.74. Outcomes concerning the disease-free survival of these patients were, however, less discrete. None of the included studies reported whether the decreased survival of patients with hydronephrosis was attributed to complications of obstructive uropathy such as uremia and sepsis. Thus, it remains, to date, unclear whether placement of ureteral stents or percutaneous nephrostomy may actually benefit these patients. More studies are needed to evaluate the actual impact of hydronephrosis on survival rates at the various stages of cervical cancer and to help establish consensus regarding the optimal mode of management of these patients.</p> 2019-01-15T11:43:22+01:00 ##submission.copyrightStatement##